Panobinostat-Bortezomib/Dexamethason bei rezidiviertem Multiplen Myelom (#599)
Laufzeit: 01.01.2015 - 31.12.2015
imported
Kurzfassung
An open-label, multi-center, expanded treatment protocol of oral panobinostat in combination with bortezomib and dexamethasone in patients with relapsed, and relapsed and refractory multiple myeloma
